- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04756219
Beneficial and Harmful Effects of Reducing Public Suicide Stigma
June 9, 2021 updated by: Nathalie Oexle, University of Ulm
There is growing evidence that negative attitudes towards persons affected by suicide (i.e.
persons who experience suicidality, persons who lost a loved one to suicide), so called public suicide stigma, is harmful for suicide prevention, for example by reducing social support, inhibiting help-seeking for suicidality and increasing distress as well as suicidality among stigmatized persons.
Reducing public suicide stigma could therefore be an important factor of successful suicide prevention.
However, reducing public suicide stigma could also be harmful, for example by increasing attitudes that suicidal behaviour is a normal and acceptable solution for crisis situations, which could decrease help-seeking for suicidality and encourage suicidal behaviour.
This project will (1) develop four interventions (contact-based vs. education based, video vs. text) hypothesized to reduce public suicide stigma, (2) determine the efficacy of the four interventions with regard to reducing public suicide stigma, (3) identify additional harmful (e.g.
normalization of suicidal behaviour) and beneficial intervention effects (e.g.
improved attitudes to seek help) and (4) investigate pathways explaining intervention effects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1800
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ulm, Germany, 89075
- Ulm University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Participants need to be at least 18 years old, speak German and provide online informed consent.
Exclusion Criteria:
Persons who self-report to have experienced suicidality within three months before baseline will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Contact Video
Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
|
No additional information necessary.
|
Experimental: Contact Text
Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
|
No additional information necessary.
|
Experimental: Education Video
Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
|
No additional information necessary.
|
Experimental: Education Text
Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
|
No additional information necessary.
|
Placebo Comparator: Control Contact
Participants randomized to this group will read a personal story of a person who survived a heart attack.
|
No additional information necessary.
No additional information necessary.
|
Placebo Comparator: Control Education
Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
|
No additional information necessary.
No additional information necessary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stigma subscale of the Stigma of Suicide Scale short form (SOSS-SF)
Time Frame: Immediately after the intervention (t1)
|
Batterham al. (2013) The Stigma of Suicide Scale.
Psychometric properties and correlates of the stigma of suicide.
Crisis 34(1):13-21
|
Immediately after the intervention (t1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stigma subscale of the Stigma of Suicide Scale short form (SOSS-SF)
Time Frame: Two weeks after the intervention (t2)
|
Batterham al. (2013) The Stigma of Suicide Scale.
Psychometric properties and correlates of the stigma of suicide.
Crisis 34(1):13-21
|
Two weeks after the intervention (t2)
|
Literacy of Suicide Scale (LOSS)
Time Frame: Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Batterham et al. (2013) Correlates of suicide stigma and suicide literacy in the community.
Suicide Life Threat Behav 43(4):406-417
|
Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Cognitions Concerning Suicide Scale (CCSS)
Time Frame: Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Cwik et al. (2017) Measuring attitudes towards suicide: Preliminary evaluation of an attitude towards suicide scale.
Compr Psychiatry 72:56-65
|
Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
General help-seeking questionnaire suicidal ideation subscale (GHSQ-SI)
Time Frame: Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Wilson et al. (2005) Measuring help-seeking intentions: Properties of the General Help-Seeking Questionnaire.
Canadian Journal of Counselling 39(1):15-28
|
Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Current suicidality
Time Frame: Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
One item adapted from the PHQ-9 (Kroenke et al. 2001; "Do you currently experience thoughts that you would be better off dead or of hurting yourself?"
response scale from 1 (not at all) to 7 (very much)
|
Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Positive and Negative Affect Schedule (PANAS), negative affect subscale
Time Frame: Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Breyer & Bluemke (2016) Deutsche Version der Positive and Negative Affect Schedule PANAS (GESIS Panel).
ZIS - GESIS Leibniz Institute for the Social Sciences
|
Immediately after the intervention (t1); Two weeks after the intervention (t2)
|
Patient Health Questionnaire (PHQ-2)
Time Frame: Two weeks after the intervention (t2)
|
Löwe et al. (2005) Detecting and monitoring depression with a two-item questionnaire (PHQ-2).
Journal of Psychosomatic Research 58(2):163-171
|
Two weeks after the intervention (t2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2021
Primary Completion (Actual)
March 19, 2021
Study Completion (Actual)
March 19, 2021
Study Registration Dates
First Submitted
February 11, 2021
First Submitted That Met QC Criteria
February 15, 2021
First Posted (Actual)
February 16, 2021
Study Record Updates
Last Update Posted (Actual)
June 10, 2021
Last Update Submitted That Met QC Criteria
June 9, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 352/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Anonymized data available upon personal request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Public Suicide Stigma
-
Saglik Bilimleri UniversitesiCompletedSuicide | Stigma, SocialTurkey
-
Region ÖstergötlandRegion Jönköping County; Kalmar County HospitalRecruiting
-
Université de SherbrookeRecruitingPublic HealthCanada
-
RenJi HospitalJinqiao Community Health Service Center of Pudong new area, Shanghai; Heqing... and other collaboratorsRecruiting
-
National Health Research Institutes, TaiwanCompletedPublic Health
-
Universidad Europea de MadridCompleted
-
Marmara UniversityMarmara University Scientific Research Projects Unit; THE SCIENTIFIC AND TECHNOLOGICAL...Enrolling by invitationPublic Health NursingTurkey
-
Assistance Publique Hopitaux De MarseilleUnknown
Clinical Trials on Contact Video
-
University of JazanSaudi Board of Community MedicineCompletedDepression Literacy | Depression StigmaSaudi Arabia
-
Ohio State UniversityUniversity of Missouri-Columbia; University of Alabama at Birmingham; University... and other collaboratorsCompletedEffectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity RehabilitationStroke | HemiparesisUnited States
-
Aller, Thomas A., ODJohnson & Johnson Vision Care, Inc.CompletedMyopia | Esophoria | Fixation Disparity
-
CIBA VISIONCompleted
-
National Development and Research Institutes, Inc.UnknownHIV TestingUnited States
-
Bausch & Lomb IncorporatedCompleted
-
Coopervision, Inc.Completed
-
Coopervision, Inc.CompletedAstigmatism | MyopiaUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting